FDA Brief

Warning letters Food

FDA warning letter to

Natural Hope Herbals, LLC

LowIssued Jun 10, 2021Posted Jul 13, 2021Division of Human and Animal Food Operations East II

Natural Hope Herbals' supplement website claims made nine products unapproved new drugs, FDA says.

What happened

In March 2021, FDA reviewed Natural Hope Herbals' website and found it took orders for nine supplement products. FDA said website and newsletter claims showed the products were intended to treat, cure, mitigate, or prevent diseases. FDA also said Prostate Health and Kidney/Bladder were intended for conditions that laypeople cannot safely self-diagnose or treat.

What FDA found

  1. Website and newsletter claims said the supplements would treat, cure, mitigate, or prevent diseases, so FDA treats them as drugs.

    Federal Food, Drug, and Cosmetic Act section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]
  2. The products are unapproved new drugs because FDA has not found them generally recognized as safe and effective for those uses.

    section 201(p) [21 U.S.C. § 321(p)]; sections 301(d) and 505(a) [21 U.S.C. §§ 331(d) and 355(a)]
  3. Prostate Health and Kidney/Bladder lack adequate directions for use because their intended diseases require a licensed practitioner's supervision.

    section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  4. Selling these misbranded drugs in interstate commerce violates the Act.

    section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of steps taken to correct the violations, including how it will prevent recurrence and supporting documents. If corrections cannot be completed in that time, the company must explain the delay and give a completion date.

Who should pay attention

  • dietary supplement brands that make disease claims
  • online herbal and tonic sellers
  • companies marketing prostate or urinary products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk